In addition, data from the DAPA-HF [7] and the EMPEROR reduced trial [8] suggest that SGLT2 inhibitors may reduce HF related endpoints and CV death even independent of the presence of diabetes.The underlying mechanisms of these beneficial effects of SGLT2 inhibitors on HF-related events remain unclear but changes in blood pressure, blood glucose, or body weight are unlikely to solely explain the observed results. The gene discussed is SLC5A2; the disease is diabetes mellitus.